Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence

Shi, Rong; Qu, Ning; Luo, Ting; Xiang, Jun; Liao, Tian; Sun, Guo Hua; Wang, Yu; Huang, Chenlu; Ji, Qing

doi:10.1089/thy.2016.0228

Cited by 60 publications

(69 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PD-L1 expression in WDTC was reported as early as 2013 and was associated with aggressive features [48]. In papillary thyroid carcinoma, PD-L1 expression appears to occur in approximately 50% of tumors and is associated with decreased disease-free survival [43][49]. It is not clear what is responsible for the decreased rate of PD-L1 positivity in PDTC compared to PTC.…”

Section: Discussionmentioning

confidence: 99%

PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma

et al. 2018

View full text Add to dashboard Cite

Poorly differentiated thyroid carcinoma (PDTC) is an aggressive form of thyroid cancer that currently has limited effective treatment options. Immune checkpoint inhibitors (ICIs) have shown to be an effective treatment for a variety of carcinomas. In this study, we explore whether immune checkpoint pathways, such as programmed cell death ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase 1 (IDO1), are activated in a cohort of patients with PDTC to determine whether ICIs may be an effective therapy for these patients. PDTC from 28 patients were stained for IDO1, PD-L1, and CD8 using immunohistochemistry. Staining was scored using an H-score, and PD-L1 and IDO1 expression was correlated with clinicopathologic characteristics. Positivity for PD-L1 and IDO1 was set at an H-score cutoff of five. Twenty-five percent (n = 7/28) of the PDTC were positive for PD-L1 expression. Twenty-nine percent (n = 2/7) of the PD-L1 positive PDTCs also co-expressed IDO1. The expression of PD-L1 in PDTC was significantly associated with tumor size and multifocality, with a non-significant trend towards associations with older age, extrathyroidal extension, presence of metastasis, higher stage, increased number of CD8+ T cells, and decreased disease-free and overall survival. PD-L1 expression occurs in a subset of PDTC, and is associated with a subset of clinical features of aggressive thyroid disease. Given the limited effective treatments for this patient population, consideration for ICIs as monotherapy or in combination with an IDO1 inhibitor should be explored as a novel treatment modality for patients with PDTC.

show abstract

Section: Discussionmentioning

confidence: 99%

PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Regarding thyroid tumors, a few papers have reported on PD-L1 expression in thyroid (Cunha et al 2013, Angell et al 2014, Wu et al 2015, Bastman et al 2016, Chowdhury et al 2016, Ahn et al 2017, Shi et al 2017). With the exception of two studies on anaplastic (undifferentiated) thyroid carcinoma (ATC) (Wu et al .…”

Section: Dear Editormentioning

confidence: 99%

“…With the exception of two studies on anaplastic (undifferentiated) thyroid carcinoma (ATC) (Wu et al . 2015, Ahn et al 2017), these studies were focused primarily on follicular cell-derived tumors (differentiated thyroid carcinoma, DTC), including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC) and poorly differentiated thyroid carcinoma (PDTC) (Cunha et al 2013, Angell et al 2014, Bastman et al 2016, Chowdhury et al 2016, Ahn et al 2017, Shi et al 2017). For these tumors (i.e., DTC), immunotherapy could be considered in the small minority of cases that are classed as refractory to radioiodine treatment.…”

Section: Dear Editormentioning

confidence: 99%

Very low expression of PD-L1 in medullary thyroid carcinoma

Bongiovanni¹,

Rebecchini²,

Saglietti³

et al. 2017

Endocrine-Related Cancer

View full text Add to dashboard Cite

“…Furthermore, a log‐rank test failed to demonstrate PD‐L1 expression as a prognostic marker. Another study reported that PD‐L1 expression was present in 52.3% of PTCs . However, in contrast, positive PD‐L1 staining was linked to multifocality and extrathyroidal extension.…”

Section: Well‐differentiated Thyroid Carcinomamentioning

confidence: 99%

“…However, in contrast, positive PD‐L1 staining was linked to multifocality and extrathyroidal extension. Furthermore, PD‐L1 expression was associated with worse recurrence‐free survival . These studies highlight some of the challenges that pathologists and cytopathologists could face with the interpretation of PD‐L1 immunohistochemical stains.…”

Section: Well‐differentiated Thyroid Carcinomamentioning

confidence: 99%